Tyra Biosciences (NASDAQ:TYRA) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Tyra Biosciences (NASDAQ:TYRA) in a research note released on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $54.00 target price on the stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright increased their price target on Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Piper Sandler lifted their price objective on Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a report on Friday, March 20th. Jefferies Financial Group upped their price objective on Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. Cantor Fitzgerald assumed coverage on Tyra Biosciences in a report on Tuesday, February 24th. They issued an “overweight” rating on the stock. Finally, Wedbush raised their target price on Tyra Biosciences from $37.00 to $53.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Tyra Biosciences Stock Up 0.4%

TYRA opened at $35.12 on Tuesday. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -17.47 and a beta of 0.96. The firm has a 50 day moving average price of $34.69 and a 200-day moving average price of $26.06. Tyra Biosciences has a twelve month low of $7.80 and a twelve month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). As a group, analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its position in Tyra Biosciences by 28.2% in the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after buying an additional 89,024 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Tyra Biosciences by 21.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after buying an additional 13,896 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Tyra Biosciences during the 1st quarter valued at about $931,000. Jane Street Group LLC bought a new position in shares of Tyra Biosciences during the 1st quarter valued at approximately $324,000. Finally, Geode Capital Management LLC grew its stake in shares of Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock valued at $5,428,000 after acquiring an additional 50,836 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.